Huisheng Biotech (300871.SZ) announced first-quarter results, changing profit to loss to RMB 16.4056 million
Huisheng Biotech (300871.SZ) released its report for the first quarter of 2024. The company's revenue was 2.07...
Huisheng Biotech (300871.SZ): Net profit is expected to drop 52.57% to 63% year-on-year in 2023
On April 10, Gelonghui | Huisheng Biotech (300871.SZ) announced that it expects net profit of 19.5 million yuan to 25 million yuan in 2023, down 52.57% to 63% from the same period last year, after deducting non-net loss of 8.5 million yuan to 13 million yuan. In the early stages, the company did not accrue individual credit impairment losses on accounts receivable from individual customers based on a comprehensive assessment of factors such as customer repayment conditions, financial changes, and development trends in the pig breeding industry. Due to the company's recent acquisition of new information, the customer showed signs of business risk and intended to apply to the court for restructuring and pre-restructuring
Huisheng Biotech (300871.SZ) plans to raise no more than 250 million yuan in capital from enterprises controlled by actual controllers, with an issue price of 9.57 yuan/share
Huisheng Biotech (300871.SZ) disclosed plans to issue A-shares to specific targets in 2024. This issuance...
Hvsen Biotechnology Co., Ltd.'s (SZSE:300871) 30% Jump Shows Its Popularity With Investors
Hvsen Biotechnology Co., Ltd. (SZSE:300871) shareholders are no doubt pleased to see that the share price has bounced 30% in the last month, although it is still struggling to make up recently lost gr
Huisheng Biotech (300871.SZ): 2023 Employee Stock Ownership Plan Non-transactional Transfer Completed
Gelonghui, Feb. 8, 丨 Huisheng Biotech (300871.SZ) announced that on February 7, 2024, the company received a “Securities Transfer Registration Confirmation” issued by the Shenzhen branch of China Securities Registration and Settlement Co., Ltd., and 1,635,450 shares of the company's shares held by the “Wuhan Huisheng Biotechnology Co., Ltd. Repurchase Special Securities Account” were transferred to “Wuhan Huisheng Biotechnology Co., Ltd. - 2023 Employee Stock Ownership Plan” on February 6, 2024. The number of shares transferred accounts for 0.99% of the company's total share capital. 10.00 yuan/share. All companies
Huisheng Biotech (300871.SZ): Proposed 2023 employee shareholding plan, the total amount raised will not exceed 167.385 million yuan
Gelonghui, December 27丨Huisheng Biotech (300871.SZ) announced the 2023 employee shareholding plan (draft). The total amount of capital to be raised in the employee shareholding plan is not more than RMB 16.7385 million. Using “shares” as the subscription unit, each share is 1.00 yuan. The maximum number of shares in the employee shareholding plan is 16.7385 million shares. After review and approval by the company's shareholders' meeting, the employee's shareholding plan will use 10 yuan/share to repurchase the shares already repurchased by the company's special securities account. The participants in this employee stock ownership plan are company directors (excluding independent directors), supervisors, and senior management.
Huisheng Biology (300871.SZ): The tylosin project with an annual output of 1,000 tons, the tylosin production line expansion project with an annual output of 1,000 tons, and the tyomycin production line expansion project with an annual output of 600 tons
Glonghui October 30 | Huisheng Biotech (300871.SZ) held an investor relations event on October 29, 2023, on “How is the company's raw material project progressing?” The company replied that the company's tylosin project with an annual output of 1,000 tons, an annual tylosin production line expansion project with an annual output of 1,000 tons, and a tyomycin production line expansion project with an annual output of 600 tons have been fully completed and put into operation. Currently, through continuous optimization of strains and process improvements, tylosin production costs are gradually trending towards the industry average. As capacity utilization increases to create scale effects and further optimization of strains and processes, API projects are imminent
Huisheng Biotech (300871.SZ): Fund-raising projects have been completed and put into operation one after another and are in a climbing phase
Glonghui, Oct. 19丨Some investors asked Huisheng Biotech (300871.SZ) on the investor interactive platform. “What was the production capacity situation in the third quarter?” The company said that the company's fund-raising projects have been completed and put into operation one after another and are in a climbing period.
Huisheng Biotech (300871.SZ): Does not revise the “Huisheng Convertible Bonds” stock conversion price downward
Glonghui September 13 | Huisheng Biotech (300871.SZ) announced that as of September 13, 2023, the stock price of Wuhan Huisheng Biotechnology Co., Ltd. from August 24, 2023 to September 13, 2023, had a situation where the closing price for at least 15 out of 30 consecutive trading days was lower than 85% of the conversion price, triggering a downward revision of the “Huisheng Bonds” conversion price. Following deliberation and approval at the sixth meeting of the third board of directors of the company, the board of directors of the company decided not to revise the share conversion price downward at this time, and within six months from the next trading day of review and approval by the board of directors (2
Huisheng Biotech (300871.SZ) released first-half results, net profit of 158.9979 million yuan, an increase of 144.11%
Huisheng Biotech (300871.SZ) released the 2023 semi-annual report. The company's revenue was 449 million...
Is Hvsen Biotechnology Co., Ltd.'s (SZSE:300871) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Hvsen Biotechnology's (SZSE:300871) stock is up by a considerable 29% over the past month. Given that stock prices are usually aligned with a company's financial performance in the long-term, we dec
Shareholders 46% loss in Hvsen Biotechnology (SZSE:300871) partly attributable to the company's decline in earnings over past year
It's nice to see the Hvsen Biotechnology Co., Ltd. (SZSE:300871) share price up 15% in a week. But that is minimal compensation for the share price under-performance over the last year. After all
4.2105 million restricted shares of 300871.SZ will be listed and circulated on December 27th.
Zhitong Financial App News, Huisheng Biological (300871.SZ) announcement, the company's pre-IPO restricted shares to lift the restrictions on the number of 4.2105 million shares, accounting for 2.53% of the company's total share capital, listing and circulation date is December 27th, 2021 (Monday).
Huisheng Biological (300871.SZ) shareholder Deep Venture Capital and its concerted actors have reduced their holdings by 3% for more than half of the time.
Zhitong Financial App News, Huisheng Biological (300871.SZ) issued an announcement The company recently received shareholders Shenzhen Innovation Investment Group Co., Ltd. (referred to as "Deep Venture Capital") and its concerted actors Shenzhen laterite Biological Venture Capital Co., Ltd. (referred to as "laterite biology"). Hubei laterite Venture Capital Co., Ltd. (Hubei laterite Venture Capital Co., Ltd.), Wuhan laterite Innovation Venture Capital Co., Ltd. (Wuhan laterite Innovation Venture Capital Co., Ltd.) issued a letter of notification on the progress of the shareholder reduction plan. The reduction plan has been implemented for more than half of the time. As of the date of disclosure of this announcement, the company's shareholders, Deep Venture Capital and its concerted actions, laterite creatures,
The result of online success of 300871.SZ convertible bonds revealed that there are a total of 224722 successful signatures.
300871.SZ disclosed the online winning result of issuing convertible corporate bonds to unspecified targets. The details are as follows: where investors participating in online purchase of Huisheng convertible bonds hold the same Mantissa of the application number as the above-mentioned number, it will be the winning number. There are a total of 224722 winning numbers, each winning number can only subscribe for 10 (1000 yuan) Huisheng convertible bonds.
Huisheng Biological (300871.SZ): deep Venture Capital and its actors have reduced their shareholdings by 1%.
300871.SZ announced that on December 16, 2021, the company received a notification letter from shareholders Deep Venture Capital and its concerted actors, laterite, Hubei laterite and Wuhan laterite, on the reduction of their shareholdings in Wuhan Huisheng Biotechnology Co., Ltd., during the period from December 10, 2021 to December 15, 2021. Shareholders Deep Venture Capital and its concerted actors laterite, Hubei laterite and Wuhan laterite reduced their holdings of 1.6625 million shares of the company through centralized bidding, accounting for 1.00% of the total share capital of the company.
Huisheng Biological (300871.SZ) shareholder Deep Venture Capital and its concerted actors have accumulated 1.6625 million shares reduced.
Zhitong Financial App News, 300871.SZ issued an announcement that on December 16, 2021, the company received a letter from shareholders of Deep Venture Capital and its concerted actions, laterite biology, Hubei laterite and Wuhan laterite, on the reduction of their shareholdings in Wuhan Huisheng Biotechnology Co., Ltd. Between December 10, 2021 and December 15, 2021, the company received a notification letter from shareholders on the reduction of their shareholdings in Wuhan Huisheng Biotechnology Co., Ltd. between December 10, 2021 and December 15, 2021. Shareholders Shenzhen Venture Capital and its concerted actors laterite, Hubei laterite and Wuhan laterite reduced their holdings of 1.6625 million shares of the company through centralized bidding, accounting for 1.00% of the total share capital of the company.
Huisheng Bio: it is proposed to issue convertible bonds of no more than 700 million yuan for projects with an annual output of 1000 tons of tylosin.
Gelonghui announced on December 14 that it intends to issue convertible bonds to raise no more than 700 million yuan for the expansion of the production line with an annual production capacity of 1000 tons of tylosin and 600tons of tylosin.
The latest announcement of Huisheng Biology: it intends to issue convertible bonds of no more than 700 million yuan for projects such as annual production of 1000 tons of tylosin.
Huisheng Biological announced that it intends to issue convertible bonds to raise no more than 700 million yuan, which will be used for the expansion project of annual production line of 1000 tons of tylosin and 600tons of tylosin. The chairman of the company is Zhang Weiyuan. Zhang Weiyuan, male, born in 1969, Chinese nationality, master of business administration and bachelor degree in animal husbandry and veterinary medicine, senior veterinarian, no permanent residence abroad. He once served as a technician in Wuhan chicken breeding farm and the person in charge of Wuhan Huaxing Feed Science and Technology Development Co., Ltd. Founded in January 2002, Huisheng Co., Ltd. has served as a director and general manager of the company. The current chairman and general manager of the company. This article is based on the Securities Star data Center.
Huisheng Biological (300871.SZ): Huisheng convertible debt will start to apply for purchase on December 17th.
Zitong Financial App News, 300871.SZ issued a notice to issue convertible corporate bonds to unspecified objects, this time a total of 700 million yuan of convertible bonds, convertible bonds referred to as "Huisheng convertible bonds", the bond code is "123132". The amount of convertible bonds that the original shareholder may give priority to place shall be the number of shares of the issuer registered after the closing of the equity registration date (December 16, 2021). The amount of convertible bonds can be calculated according to the proportion of 4.2105 yuan per share of convertible bonds, and then the number of convertible bonds will be converted into convertible bonds, each of which will be a unit of application.
No Data